Opinion

Video

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

Author(s):

Barbara Burtness, MD,Victoria M. Villaflor, MD

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Video content above is prompted by the following:

  • What further research is needed to better understand the long-term benefits and risks of neoadjuvant/adjuvant PD-1 blockade this patient population?
Related Videos
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
2 KOLs are featured in this series.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Versamune HPV in HPV16-Driven HNSCC ©stock.adobe.com
November 18th 2024

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

David A. Braun, MD, PhD
November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors